Table 2.
Mean baseline and follow-up scores.
| Scale | Guanfacine, n = 30 Mean (95% CI) | % Change | Placebo, n = 32 Mean (95% CI) | % Change | Group difference mean (95% CI) | P-value* |
|---|---|---|---|---|---|---|
| HSQ-ASDa | ||||||
| Baseline | 3.4 (2.8–4.0) | 3.3 (2.8–3.8) | ||||
| Week 2 | 2.2 (1.7–2.7) | −35% | 3.0 (2.5–3.5) | −9% | −0.8 (−1.5 to −0.1) | 0.0316 |
| Week 4 | 1.6 (1.1–2.1) | −53% | 2.5 (1.9–3.0) | −24% | −0.8 (−1.6 to −0.1) | 0.0209 |
| Week 8 | 1.9 (1.4–2.4) | −44% | 2.9 (2.4–3.4) | −12% | −1.0 (−1.7 to −0.3) | 0.0042 |
| CASI Anxietyb | ||||||
| Baseline | 14.0 (10.1–17.8) | 15.8 (11.8–19.8) | ||||
| Week 8 | 10.8 (8.7–12.9) | −23% | 11.6 (8.8–14.5) | −27% | −0.8 (−4.3 to 2.7) | 0.64 |
| CYBOCS-ASDc | ||||||
| Baseline | 11.2 (9.3–13.1) | 10.9 (9.0–12.9) | ||||
| Week 8 | 8.5 (6.9–10.1) | −24% | 10.8 (9.9–11.8) | <−1% | −2.3 (−4.1 to −0.5) | 0.0143 |
| CSHQd | ||||||
| Baseline | 44.0 (42.1–45.9) | 44.4 (42.9–45.9) | ||||
| Week 8 | 44.0 (42.6–45.4) | 0% | 43.7 (42.4–45.0) | −2% | 0.31 (−1.59 to 2.20) | 0.75 |
Note: Raw mean scores at baseline and least squares (LS) mean values (adjusted for baseline scores) for follow-up scores
aHSQ-PDD score is per item mean from 24 items
bCASI Anxiety score is a total score of 20 items
cCYBOCS-ASD score is a total score of 5 items
dCSHQ score is a total score for 27 items
*Adjusted LS means differences between guanfacine and placebo groups
P-values are bolded if statistically significant at p less than or equal to 0.05. The p-value is for differences between adjusted LS means for the two treatment groups at the specified time points.